APVO Earnings

Quarterly EPS
$-6441.48
Q3 2024
$-2129.68
Q4 2024
$-1581.81
Q1 2025
$-151.29
Q2 2025
$-40.14
Q3 2025
$0.00
Q4 2025
$-6.41
Q1 2026
$-5.31
Q2 2026
Latest RevenueN/A
Latest Net Income-6356000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$5.310-6356000+96.5%
Q1 2026-$6.410-6697000+99.6%
Q4 20250-5806000
Q3 2025-$40.140-7549000+99.4%
Q2 2025-$151.290-6204000+99.3%
Q1 2025-$1,581.810-6408000+98.8%
Q4 2024-$2,129.680-6312000+97.0%
Q3 2024-$6,441.480-5101000+97.8%
Q2 2024-$22,265.280-5883000
Q1 2024-$132,555.600-6834000
Q4 2023-$71,560.040-5903000
Q3 2023-$295,171.200-6334000
Aptevo Therapeutics (APVO) — Earnings